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Immunochromatographic test (ICT) kits for the rapid detection of immunoglobulin G (IgG) and IgM
antibodies to Burkholderia pseudomallei were compared to the indirect hemagglutination (IHA) assay. In 138
culture-confirmed melioidosis cases, sensitivities were 80, 77, and 88% for IHA, ICT IgG, and ICT IgM,
respectively. In a prospective study of 160 consecutive sera samples sent for melioidosis serology, respective
specificities were 91, 90, and 69, positive predictive values were 41, 32, and 18, and negative predictive values
were 99, 98, and 100%. ICT IgM kits are unreliable for diagnosis of melioidosis, but ICT IgG kits may be useful
for diagnosing travelers presenting with possible melioidosis who return from regions where melioidosis is
endemic.
Melioidosis is the infectious disease caused by the soil and
water bacterium Burkholderia pseudomallei. Melioidosis is
most commonly described from southeast Asia and northern
Australia, but the area where this disease is endemic includes
India and China, and imported cases are increasingly being
recognized in Europe and the United States (2, 5, 12). Defin-
itive diagnosis requires positive bacterial culture and confir-
mation of the organism, which usually takes several days. Fur-
thermore, B. pseudomallei is resistant to many standard
antibiotics used in empirical therapy for sepsis (12). Therefore,
various antigen and nucleic acid detection tests and serology
assays have been developed to expedite diagnosis (1, 6, 9, 10,
11). A commercially available immunochromatographic test
(ICT) kit for the rapid determination of immunoglobulin M
(IgM) and IgG antibodies to B. pseudomallei has been devel-
oped, with excellent sensitivity and specificity reported (4). We
have evaluated this kit in an area of northern Australia where
melioidosis is endemic.
Melioidosis Rapid Cassette Test kits were supplied by Pan-
Bio (Windsor, Queensland, Australia), and sera were tested
and reported according to the manufacturer’s instructions,
which have been slightly modified from the previously de-
scribed methods (4). Briefly, 5 l of serum was placed on each
of the target areas of the separate IgG and IgM test cassettes.
Three drops of kit buffer were then added, and after 15 min the
results were read; any trace of a pink-purple line was recorded
as a positive result. All sera were also tested by standard B.
pseudomallei indirect hemagglutination (IHA) assay, with a
titer of 1:40 considered reactive in our examination. A de-
finitive diagnosis of melioidosis was the culture of B.
pseudomallei from patient clinical specimens by using standard
bacterial identification methods (3).
We first analyzed sera from 138 culture-confirmed cases of
melioidosis for which the sera had been collected within 5 days
of admission and stored until tested at 70°C. Positive results
were 110 for IHA (sensitivity, 79.7%), 121 for ICT IgM (sen-
sitivity, 87.7%), and 106 for ICT IgG (sensitivity, 76.8%).
Twenty of these patients had presented with chronic melioid-
osis, defined as symptoms being present for more than 2
months (3). In this subset sensitivities were 95, 100, and 95%
for IHA, ICT IgM, and ICT IgG, respectively.
To ascertain the specificity and predictive values of the as-
says, we prospectively tested all patients who had sera sent for
melioidosis serology at Royal Darwin Hospital over a 6-week
period in early 2003, during the monsoonal wet season when
most cases of melioidosis occur in our region (3). Sera from
patients with past melioidosis were excluded from analysis,
leaving 160 patients. Results are shown in Table 1. During that
period, 10 new cases of melioidosis were confirmed by positive
culture. For the other 150 patients the cultures for B.
pseudomallei were negative, and none of these patients was
treated as having culture-negative melioidosis or developed
melioidosis over the subsequent 12 months, with active surveil-
lance continued for those with positive serology.
While the ICT IgM had good sensitivity, false-positive re-
sults were common in the prospective study, with a specificity
of only 68.7% and a positive predictive value of only 17.5%.
These data are very different from the 95% specificity previ-
ously reported for the assay (4). In the earlier study specificity
was calculated from the testing of a combination of laboratory
and blood donor samples (4). False-positive IgM tests are well
recognized for various infections, and it has been recom-
mended that assessment of assay specificity and predictive val-
ues be undertaken with prospectively collected samples from
the population for whom the assay is being used (7, 8). Fur-
thermore, reported sensitivities and specificities have been
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found to be higher when studies of new serological assays have
not followed such recommendations. We believe sample selec-
tion, and not technical differences in performing the assay,
accounts for the difference between our results and those of
the earlier study. By prospectively testing all patients referred
for melioidosis serology, we conclude that the current ICT IgM
test is not reliable for predicting melioidosis, having a low
positive predictive value.
The ICT IgG test gave results very similar to those of IHA,
which remains the most widely used serology assay for melioid-
osis (10). For both assays a level of background seropositivity
is expected because of prior exposure to B. pseudomallei in
areas where melioidosis is endemic (12), and this may well
account for the low positive predictive value for active disease
(melioidosis) in our region. However, the specificities deter-
mined in this study of 90 and 91.3%, respectively, suggest
serology remains useful for selecting patients for more inten-
sive culturing for B. pseudomallei. Negative initial serology in
acute melioidosis is well recognized, and sensitivities in this
study demonstrate that negative serology cannot be used to
exclude melioidosis, especially early in acute disease. False-
negative serology is less common with chronic melioidosis,
occurring in only 1 of 20 patients in this study.
The ICT IgG cassette kit has the advantages of being trans-
portable, user friendly, and able to produce an immediate
result. It could be useful in hospital laboratories in areas where
the disease is not endemic for rapid single-sample testing of
patients with possible imported melioidosis. In these situations
background seropositivity is less likely, especially in returning
travelers. While patients presenting with acute melioidosis may
initially have a negative ICT IgG result, the positive and neg-
ative predictive values should be especially high for those pre-
senting with chronic symptoms consistent with melioidosis in
areas where the disease is not endemic. This is an increasingly
common clinical scenario, as more people with risk factors
from the United States, Europe, and other locations where
melioidosis is not endemic travel to regions where melioidosis
is endemic (2). Nevertheless, culture of B. pseudomallei re-
mains the gold standard for the diagnosis of melioidosis. A
positive ICT IgG result could suggest the need for further
appropriate cultures in laboratories not experienced with iso-
lating and identifying B. pseudomallei. Cultures in selective
media of throat and rectal swabs and any skin lesions are
recommended, as is careful attention to correct identification
of any gram-negative organisms isolated from blood and sterile
sites.
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TABLE 1. IHA, ICT IgM, and ICT IgG results for 160
prospectively studied patientsa
Serology test
Test results (%)
Sensitivity Specificity PPVb NPVc
IHA 90 91.3 40.9 99.3
ICT IgM 100 68.7 17.5 100
ICT IgG 70 90 31.8 97.8
a Of the 10 samples culture positive for melioidosis, 9 were positive by IHA
and 1 was negative; for ICT IgM, 10 were positive and 0 were negative; for ICT
IgG, 7 were positive and 3 were negative. Of the 150 samples that were culture
negative for melioidosis, 13 were positive by IHA and 137 were negative; for ICT
IgM, 47 were positive and 103 were negative; for ICT IgG, 15 were positive and
135 were negative.
b PPV, positive predictive value, which is the number of true positives out of
the total number of positives.
c NPV, negative predictive value, which is the number of true negatives out of
the total number of negatives.
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